Search results
Results from the WOW.Com Content Network
[citation needed] For example, the equivalent dose of diazepam in an elderly individual on lorazepam may be half of what would be expected in a younger individual. [7] [8] Equivalent doses of benzodiazepines differ as much as 20 fold. [9] [10] [11]
A box of Lorazepam Orion (Lorazepam) tablets. Lorazepam, sold under the brand name Ativan among others, is a benzodiazepine medication. [14] It is used to treat anxiety (including anxiety disorders), trouble sleeping, severe agitation, active seizures including status epilepticus, alcohol withdrawal, and chemotherapy-induced nausea and vomiting. [14]
In the elderly, long-term benzodiazepine therapy is a risk factor for amplifying cognitive decline, [29] although gradual withdrawal is associated with improved cognitive status. [30] A study of alprazolam found that 8 weeks administration of alprazolam resulted in deficits that were detectable after several weeks but not after 3.5 years.
High doses of many shorter-acting benzodiazepines may also cause anterograde amnesia and dissociation. [4] These properties make benzodiazepines useful in treating anxiety, panic disorder, insomnia, agitation, seizures, muscle spasms, alcohol withdrawal and as a premedication for medical or dental procedures. [5]
Commonly prescribed benzodiazepines in the U.S. are Valium (diazepam) and Ativan (lorazepam), which are used for muscle relaxation and to control anxiety and seizures. While Rohypnol falls into ...
Ativan – a benzodiazepine, used to treat anxiety Asendin ( amoxapine ) – an dibenzoxazepine antidepressant Azstarys ( Serdexmethylphenidate / Dexmethylphenidate ) - a long-acting CNS stimulant used to treat ADHD
A high degree of tolerance often occurs in chronic benzodiazepine abusers due to the typically high doses they consume which can lead to a severe benzodiazepine dependence. The benzodiazepine withdrawal syndrome seen in chronic high dose benzodiazepine abusers is similar to that seen in therapeutic low dose users but of a more severe nature ...
Lilly’s Zepbound, approved in November 2023 as the Indiana-based drug giant’s answer to Novo Nordisk’s Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its Phase ...